INNOVATE Corp.

INNOVATE Corp.

VATE
INNOVATE Corp.US flagNew York Stock Exchange
7.16
USD
+0.08
- -
97.68MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
162.8
275.07
419.55
414.53
378.48
442.33
238.31
141.5
155.2
209.75
182.09
103.5
94.27
113.73
Basic EPS, GAAP
78.76
-8.26
-14.92
-28.04
-11.51
34.82
-6.97
-18.87
-29.58
-5.23
-4.81
-3.35
-4.84
-1.8
Free Cash Flow per Basic Share
-23.21
-0.04
-18.43
13.33
-5.86
67.51
19.03
4.6
0.37
-3.87
1.04
-0.93
9.12
7.95
Dividend per Share
85.41
0.82
2.13
1.12
0.83
0.45
- -
- -
0.37
0.67
0.28
0.11
0.17
0.14
Book Value per Share
37.91
16.38
11.65
3.5
10.5
14.97
73.05
71.09
-13.15
-15.29
-20.74
-13.6
-17.58
-17.83
Tangible Book Value per Share
35.56
-9.31
-13.84
-29.17
-45.31
-71.32
3.98
34.46
-55.98
-55.26
-59.08
-36.16
-38.98
-28.8
Basic Weighted Avg Shares
1
2
3
4
4
4
5
5
8
8
8
11
13
13
Sales/Revenue/Turnover
231
547
1,121
1,558
1,634
1,977
1,077
717
1,205
1,637
1,423
1,107
1,246
1,516
Operating Margin (%)
-15.76
-2.53
0.06
-0.1
-0.07
-2.77
6.99
-3.95
-0.88
0.82
1.86
3.61
2.3
4.28
Depreciation Expense
24
11
32
29
37
39
8
27
38
42
36
33
30
30
Net Income, GAAP
112
-14
-36
-94
-47
162
-32
-92
-228
-36
-35
-35
-61
-22
Effective Tax Rate (%)
- -
- -
- -
- -
- -
1.32
- -
- -
- -
- -
- -
- -
- -
51.37
Profit Margin (%)
48.38
-2.63
-3.17
-6.07
-2.87
8.2
-2.92
-12.83
-18.88
-2.19
-2.47
-3.13
-4.86
-1.48
Working Capital
43
118
1,953
1,969
2,010
4,896
5,584
294
3
121
105
-92
-582
-604
LT Debt
- -
336
370
428
593
710
660
160
615
738
728
544
123
118
Total Equity
54
108
121
70
190
202
455
606
-7
-47
-153
-160
-225
-230
Return on Invested Capital (%)
- -
- -
- -
- -
- -
-6.16
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
25.03
- -
- -
- -
- -
- -
- -
- -
28.01
Return on Common Equity (%)
181.6
-35.07
-98.7
-375.31
-161.48
271.55
-15.47
-21.51
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
594
625
564
LT Borrowings
80
69
62
LT Finance Leases
43
72
56
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
14
Market Capitalization
62
77
255

Working Capital

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
452
406
480
Cash, Cash Equivalents & STI
112
135
88
Accounts Receivable, Net
4
3
1
Inventories
16
15
15
Total Current Liabilities
1,034
1,020
1,083
Payables & Accruals
227
204
181
ST Debt
594
625
564
Deferred Revenue
172
157
183

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
104.57%
150.33%
40.55%
Free Cash Flow
-468.43%
-579.03%
-1,317.17%
Net Income, GAAP
-12.29%
26.91%
75.14%
Sales/Revenue/Turnover
6.71%
16.24%
12.55%
Total Cash Common Dividend
- -
- -
500%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
315
313
242
237
1,107
2025
274
242
347
383
1,246
2026
365
422
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-2.25
1.58
-1.18
-1.29
-3.35
2025
-1.89
-1.67
-0.71
-0.58
-4.84
2026
-1.29
0.78
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.03
0.02
0.02
0.11
2025
0.02
0.06
0.03
0.05
0.17
2026
0.03
0.02
- -
- -
- -

Company Description

CEO
Paul Kenneth Voigt
Full Time Employees
3,663
Sector
Industrials
Industry
Engineering & Construction
Address
295 Madison Avenue New York City NY United States of America 10017
IPO Date
Jul 13, 2009
Business
INNOVATE Corp. (NYSE: VATE) operates as a diversified holding company with subsidiaries focused on infrastructure, life sciences, and spectrum segments primarily in the United States; its infrastructure unit through DBM Global Inc. provides fully integrated construction and professional services including design-assist, modularization, fabrication and erection of structural steel, heavy steel plate, trusses and girders, heavy equipment installation, as well as facility maintenance and shutdown services for critical sectors such as infrastructure and energy; the life sciences segment encompasses Pansend Life Sciences developing innovative healthcare technologies to address unmet needs, R2 Technologies offering an FDA-cleared device to soothe, brighten skin and treat visible signs of aging caused by inflammation in the global aesthetic dermatology market, and MediBeacon providing the FDA-approved Transdermal GFR System (TGFR), a point-of-care product for assessing kidney function in patients with normal or impaired renal function targeting a $7 billion market; the spectrum segment operates through HC2 Broadcasting Holdings Inc. and subsidiaries, owning and managing one of the largest broadcast station groups in the U.S. with 256 stations in 106 markets and 2.3 billion MHz POPs of spectrum for over-the-air broadcasting. Founded in 1994 and headquartered at 295 Madison Avenue, 12th Floor, New York, New York, the company, formerly known as HC2 Holdings, Inc. and tracing roots to Primus Telecommunications Group, rebranded to INNOVATE Corp. in September 2021 to emphasize innovative growth businesses across its portfolio serving industrial, healthcare, biotechnology, and media markets. In a significant recent development, INNOVATE Corp. completed a comprehensive debt refinancing in August 2025, restructuring 81.7% of its total outstanding principal debt as of June 30, 2025, by exchanging $328.1 million of existing senior secured notes for new 10.500% Senior Secured Notes due 2027, $48.7 million convertible senior notes for new 9.5% Convertible Senior Secured Notes, amending various credit facilities, and exchanging preferred stock for additional note principal resulting in a $43.0 million CGIC note, while extending maturities on its revolving credit agreement to September 2026, CGIC note to April 2027, Spectrum Notes to September 2026, and R2 Technologies note to August 2026 to enhance financial flexibility.

Company News

  • INNOVATE Announces Closing of the Sale of a Controlling Interest in its Broadcasting Segment to CONX

  • VATE Q2 Earnings Improve Y/Y as Infrastructure Revenues Surge

  • MediBeacon® Transdermal GFR System Nominated for 2026 Prix Galien USA Best Medical Technology

  • IES Holdings to Acquire DBM Global

  • INNOVATE Agrees to $650 Million Sale of DBM Global to IES Holdings

  • INNOVATE Q2 Earnings Call Highlights

  • INNOVATE Corp. (VATE) Q2 2026 Earnings Call Prepared Remarks Transcript

  • INNOVATE Corp. to Report Second Quarter 2026 Results on August 6th

  • INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend

  • INNOVATE Announces Successful Closing of Broadcasting Refinancing and Agrees to Partial Sale of Broadcasting

  • INNOVATE Q1 Loss Narrows Y/Y on Infrastructure, AI Project Demand

  • INNOVATE Q1 Earnings Call Highlights

  • INNOVATE Corp. (VATE) Q1 2026 Earnings Call Prepared Remarks Transcript

  • INNOVATE Corp. Announces First Quarter 2026 Results

  • INNOVATE Corp. to Report First Quarter 2026 Results on May 14th

  • INNOVATE (NYSE:VATE) & Great Elm Group (NASDAQ:GEG) Financial Review

  • Comparing Livento Group (OTCMKTS:NUGN) and INNOVATE (NYSE:VATE)

  • INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend

  • MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation

  • INNOVATE Corp. (VATE) Q4 2025 Earnings Call Prepared Remarks Transcript